A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Squamous Non Small Cell Lung Carcinoma (sqNSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Erdafitinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FIND Trial
- 11 Jul 2019 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record
- 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.